为保障生产平稳运行，集输站建立了完善的数据统计与分析体系，将数据化管理贯穿设备维护、数据监 控、日常巡检全过程。他们提出"重要、紧急报警零容忍"的要求，报警信息产生后5分钟内响应，员工 需要快速完成识别确认并采取有效处置措施，确保外输参数、管线压力、升温降黏等关键数据及时恢复 至正常范围。 通过对各类生产数据的深度分析，精准定位工作中的问题与优化空间，制定针对性改进措施，这个集输 站实现报警确认及时率100%，以数据驱动生产决策的科学化。 与此同时，他们建立定期目标复盘机制，及时跟踪完成进度，根据生产动态调整工作策略，确保全年原 油外输效率稳定保持100%，为管理区产量目标的实现提供了有力支撑。 技能是安全生产的第一道防线。站长刘鹏坚持"因人而异、因材施教"，精准掌握每位员工的技能短板， 量身定制个性化培训计划：针对沟通能力薄弱的员工，开展沟通技巧专项培训；对业务流程不熟悉的新 人，安排经验丰富的老员工进行一对一辅导。他还与主任技师秦胜华紧密协作，将培训内容与现场实操 深度融合，通过"学练结合、对照指导"的方式，及时纠正工作中的低标准、老毛病，让培训成果直接转 化为实际操作能力。得益于这套高效的培训体系，集输 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to continue its growth driven by ongoing innovation and internationalization efforts [1][5] - The company reported a rapid profit growth and improved cash flow for 2024, with operating revenue reaching 41.067 billion yuan, a year-over-year decrease of 0.80% [1] - The company achieved a net profit of 2.770 billion yuan in 2024, an increase of 16.08% year-over-year, with a non-GAAP net profit of 2.314 billion yuan, up 15.10% [2] Summary by Sections Performance Overview - The company’s revenue for 2024 was 41.067 billion yuan, with innovative products contributing to steady growth [1] - Operating cash flow improved to 4.477 billion yuan, a year-over-year increase of 31.13% [1] Business Segmentation - The pharmaceutical segment generated revenue of 28.924 billion yuan in 2024, with a segment profit of 3.250 billion yuan, reflecting a year-over-year growth of 65.73% [3] - The medical devices and diagnostics segment reported revenue of 4.323 billion yuan, a decrease of 1.53% year-over-year, primarily due to declining COVID-related product sales [3] - The healthcare services segment achieved revenue of 7.647 billion yuan, a year-over-year increase of 14.61%, although it still reported a segment loss of 315 million yuan [4] Future Outlook - The company plans to maintain high R&D investment, with total R&D expenditure reaching 5.554 billion yuan in 2024, representing 16.98% of pharmaceutical revenue [5] - The company is advancing its internationalization strategy, with several products receiving approvals in international markets, including the US and Europe [6] - Earnings per share (EPS) forecasts for 2025-2027 are projected at 1.22, 1.37, and 1.57 yuan, respectively [12]